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Cancer patients are at major risk of developing venous thromboembolism (VTE), resulting 
in increased morbidity and economic burden. While a number of theories try to explain its 
pathophysiology, its risk stratification can be broadly done in cancer-related, treatment–
related, and patient-related factors. Studies report the prophylactic use of thrombolytic 
agents to be safe and effective in decreasing VTE-related mortality/morbidity especially 
in postoperative cancer patients. Recent data also suggest the prophylactic use of 
low molecular weight Heparins (LMWHs) and Warfarin to be effective in reducing VTEs 
related to long-term central venous catheter use. In a double-blind, multicenter trial, a 
new ultra-LMWH Semuloparin has shown to be efficacious in preventing chemotherapy- 
associated VTE’s along with other drugs, such as Certoparin and Nadoparin. LMWHs 
are reported to be very useful in preventing recurrent VTEs in advanced cancers and 
should be preferred over full dose Warfarin. However, their long-term safety beyond 
6 months has not been established yet. Furthermore, this paper discusses the safety 
and efficacy of different drugs used in the treatment and prevention of recurrent VTEs, 
including Bemiparin, Semuloparin, oral direct thrombin inhibitors, parenteral and direct 
oral factor Xa inhibitors.
Keywords: venous thromboembolism, risk stratification, newer oral anticoagulants, thromboprophylaxis, low 
molecular weight heparin, apixaban, rivaroxaban
KeY POiNTS
 ◦ Risk factors for venous thromboembolism can be grouped into three broad categories: cancer-
related, patient-related, and treatment-related factors.
 ◦ Prophylactic use of anticoagulants is safe and efficacious in preventing VTE.
 ◦ LMWHs prove to be a good treatment option for VTE in advanced cancers, being simpler and 
more efficacious in preventing recurrence.
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iNTRODUCTiON
Cancer continues to pose a costly and growing international 
threat toward modern day society. Among its many direct and 
indirect complications is its role as a major risk factor for venous 
thromboembolism (VTE), discovered in a fifth of all cancer 
patients and as many as half on postmortem examination (1, 2). 
Such VTE events include, but are not limited to, central venous 
catheter (CVC)-related thrombosis and pulmonary embolism 
(PE) (3, 4). It was Professor Armand Trosseau who first described 
the association between cancer and thrombosis in 1865, almost 
150  years ago, yet its exact pathophysiology remains poorly 
understood. Cancer-associated VTE bears several clinical and 
economic implications, including increased hospitalization 
rates, the need for anticoagulation (and its associated bleeding 
complications), in addition to the risk for recurrent VTE and the 
potential for delays in cancer therapy (5). This article presents 
an overview of VTE risk assessment in cancer patients, current 
treatment guidelines and the role of newer anticoagulants in the 
treatment of cancer-related VTE.
Disease Burden and  
economic implications
To the practicing clinician, cancer remains the most significant 
acquired risk factor for the development of VTE, with an annual 
incidence of 1 in 200, ultimately affecting at least 15% of this 
population (6). VTE in patients with underlying malignancy as 
opposed to those without cancer can be particularly more serious 
given their increased likelihood of VTE recurrence, risk of major 
bleeding complications from anticoagulants, and their reduced 
survival from such events. Prandoni et al. for instance, reported 
that patients with cancer and VTE were approximately four times 
more likely to develop recurrent thromboembolic complications 
and twice as likely to develop major bleeding while on anticoagu-
lation when compared to patients without underlying malignancy 
(7). In a retrospective analysis, Khorana et al. found that inhos-
pital mortality was two- to fivefold higher among neutropenic 
cancer patients hospitalized with thromboembolism as compared 
to those without thromboembolism. Chew and colleagues 
analyzed the effect of VTE on survival between cancer patients 
and found that a diagnosis of thromboembolism was associated 
with reduced survival rates during the first year, regardless of the 
type of cancer studied [hazard ratio (HR) 1.6–4.2, P > 0.1] (8). 
In addition to its human cost, VTE in cancer patients confers 
additional economic burden. Of cancer patients who develop 
deep vein thrombosis (DVT), the mean cost of hospitalization in 
2002 was US $20,065 (9) compared to an average between $7712 
and $10,804 for a similar episode in the general population (10).
Pathophysiology
While the exact mechanism of VTE in cancer patients is unclear, 
several theories seem to bear credence. It is recognized, for 
example, that tissue factor (TF) (which initiates the coagulation 
cascade) is itself expressed in a variety of malignancies and 
released into the circulation, suggesting its potential role in 
cancer-related VTE (8). One study was able to demonstrate a 
consistent relationship between cell surface expression of TF and 
prothrombotic potential across a range of sites, including breast, 
colorectal, and pancreatic tumor cell lines (11). Other observa-
tions have lent themselves to other theories. Falanga and Gordon 
(12), for example, described a cysteine protease that directly 
activates factor X in the absence of factor VII while Denko 
and Giaccia had proposed that tumor cell hypoxia stimulates 
production of procoagulant and angiogenic factors (13). Other 
theories based on animal models have raised the possibility of 
oncogene activation to explain the manifestations of Trousseau’s 
syndrome (14). Yet others describe release of mucins and their 
interaction with L- and P-selectins particularly in patients with 
mucinous adenocarcinomas (15, 16). It would not be unreason-
able, therefore, to assume that some of these pathways operate 
and overlap in ways that ultimately predispose the cancer patient 
to thromboembolic events.
Risk Stratification
It is difficult to directly compare the rates of cancer-related VTE 
among patients as the studies vary in their study periods, the 
methods employed in detecting and reporting VTE, the patient 
populations, and their follow-up periods. Additionally, with 
the temporal rise in the incidence of VTE, newer studies seem 
to report higher rates than those that are less recent (17,  18). 
Nevertheless, there is broad agreement in the literature with 
regards to most risk factors for cancer-related VTE. These can 
be broadly divided into three categories: cancer-related factors, 
treatment-related factors, and patient-related factors.
Cancer-Related Risk Factors
The site of the primary tumor has been established as a risk fac-
tor for VTE in a number of studies. Specific incidence rates vary 
based on the clinical setting, but some of the highest rates have 
been described in patients with primary brain tumors (19, 20), 
pancreatic (21, 22), stomach (23), uterine (24, 25), and lung 
carcinomas (26, 27). More recent studies suggest high incidence 
rates of VTE in association with hematologic malignancies as 
well. In a large population-based case-control study, hematologic 
malignancies were in fact found to confer the highest risk of 
venous thrombosis, followed by lung and gastrointestinal cancers 
(28). Even among cancer patients with the same primary site, 
VTE rates seem to vary markedly based on grade and histology. 
Blom et al., for instance, showed that lung cancer patients with 
adenocarcinoma had a greater incidence of venous thrombosis 
as compared to those with squamous cell carcinoma (29). Indeed 
the stage of cancer is also important, with more advanced stages 
of cancers conferring ever increasing risk (18, 30). It appears that 
this risk is highest in the period immediately following cancer 
diagnosis. In a large case-control study, it was reported that the 
risk of VTE was highest in the first 3 months following the diag-
nosis of cancer [adjusted odds ratio (OR), 53.5; 95% confidence 
interval (CI), 8.6–334.3], subsiding gradually over a 15-year 
period to levels observed in the general population (28).
Treatment-Related Risk Factors
As cancer patients too often know unfortunately, the remedy can 
sometimes be more toxic than the malady itself. Chemotherapy 
TABLe 1 | Clinical risk factors for cancer-associated venous 
thromboembolism.
Cancer-related factors
• Primary site of cancer (17, 18, 28, 30, 32); brain, pancreas, kidney, 
stomach, lung, gynecologic, lymphoma, myeloma
• Advanced stage of cancer (18, 30, 45)
• Initial period after diagnosis of cancer (26, 31, 54, 55)
• Histology (29, 56)
Treatment-related factors
• Major surgery (45)
• Hospitalization (32, 48, 49)
• Cancer therapy
 o Chemotherapy (3, 31, 39, 48)
 o Hormonal therapy (57)
 o Anti-angiogenic agents (33–37, 58–60)
 o Erythropoiesis-stimulating agents (40, 61)
 o Transfusions (41)
 o Central venous catheters (46, 47)
Patient-related factors
• Older age (32, 45)
• Female sex (32)
• Race (32, 43, 56)
 o Higher in African American
 o Lower in Asians/Pacific Islanders
• Comorbidities (43, 44, 48, 56, 62)
• Inherited prothrombotic mutations (28, 63); Factor V Leiden, prothrombin 
gene mutation
• Prior h/o VTE (45, 51–53)
• Performance status (26, 45)
Biomarkers (61, 62, 64, 65)
• Prechemotherapy platelet count ≥350,000
• Prechemotherapy leukocyte count >11,000
• Increased tumor cell expression of tissue factor (TF) (8, 21, 66)
Modified from Khorana et al.
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is associated with a two- to sixfold increase in the risk of VTE 
compared to the general population and in patients starting 
new chemotherapy regimens, accounts for 9% of deaths (3, 31). 
These trends seem to be increasing over time, perhaps owing 
to the development of additional chemotherapeutic options. In 
hospitalized patients receiving chemotherapy, rates of VTE rose 
from 3.9 to 5.7% from 1995 to 2003, an increase of 47% (32). 
Some chemotherapy agents appear to confer greater risk than 
others. Patients with multiple myeloma receiving Thalidomide in 
combination with dexamethasone, for example, have DVT rates 
as high as 28% in some instances (33, 34). Additional predictors 
for Thalidomide associated VTE include its combined use with 
Doxorubicin (OR = 4.3), newly diagnosed disease (OR = 2.5), 
and Chromosome 11 abnormalities (OR =  1.8) (35). Another 
commonly used agent, Lenalidomide, has significant survival 
benefits in myeloma patients while also being associated with 
rates of VTE as high as 75% (36). Another agent, Bevacizumab 
(an anti-angiogenic in use for a variety of cancers) has been asso-
ciated with increased risk of both arterial (37) as well as venous 
(38) events. Strategies to mitigate VTE events in such patients 
continue to be investigated, though intermittently dosed chemo-
therapy regimens appear to lessen such risks when compared to 
continuous treatment (39).
Even common and seemingly innocuous practices, such as the 
administration of erythropoiesis-stimulating agents (ESAs) to 
treat anemia, can be harmful in the cancer patient. In a systematic 
review of 57 trials on cancer patients, thromboembolic events 
were observed in 229 of 3,728 patients treated with Epoetin or 
Darbepoetin and in 118 of 3,041 untreated controls (RR = 1.7; 
95% CI, 1.4–2.1) (40). In hospitalized cancer patients, it is often 
necessary to transfuse blood and platelet products both of which 
are associated with an increased risk of thromboembolic events 
as well as mortality (41).
While surgery and a prolonged postoperative period are 
well-known risk factors for VTE, recent data suggest these may 
not be as significant as other factors, possibly owing to increased 
thromboprophylaxis rates among the surgical patient population 
(31, 42–44). Nevertheless, cancer patients undergoing surgery are 
still at risk for VTE events, particularly in those >60 years of age 
(OR = 2.6, 95% CI, 1.2–5.7), with prior episodes of VTE (OR = 6, 
95% CI, 2.1–16.8), advanced stages of cancer (OR = 2.7, 95% CI, 
1.4–5.2), anesthesia lasting more than 2 h (OR = 4.5, 95% CI, 1.1 
to 19), and bed rest exceeding 3 days (45).
Central venous catheters are widely used in patients with 
cancer for the administration of chemotherapy. Verso et  al. 
reported that the incidence of symptomatic catheter-related DVT 
in adults ranges from 0.3 to 28% while that of catheter-related 
DVT screened by venography ranges from 27 to 66% (46). The 
specific chemotherapy agent administered through the catheter 
can also influence the risk of DVT (47). Other treatment-related 
risk factors for VTE that have been described in the literature 
include hospitalization (48, 49) and radiation (31, 50).
Patient-Related Risk Factors
The overall risk of VTE is often affected by a multitude of 
patient-related factors, including a history of prior thrombotic 
events, comorbid conditions, genetic factors, immobility, age, 
sex, and race (Table 1). Prior thrombotic episodes significantly 
increase future thrombotic risk in a wide range of cancer patients 
including those with prostate cancer, myeloma, and cancer 
patients undergoing surgery to name a few (OR = 6.0, 95% CI, 
2.1–16.8) (51, 52). Concurrent thrombotic events, either venous 
or arterial are also thought to increase the risk for VTE (32). In 
patients with hepatocellular carcinoma, for instance, it is noted 
that the incidence of systemic VTE is higher in patients with 
concurrent portal vein thrombosis when compared to those 
without it (11.5 vs. 4.4%, P =  0.04) (53). It is suggested that 
locally occurring thrombotic events may propagate pathways 
that result in systemic hemostatic activation. In addition to 
obtaining a history of prior VTE events, one must elucidate 
details of a patient’s comorbid conditions as these are invariably 
apt to influence thrombotic risk. Khorana et  al. for instance, 
showed that infections (OR = 1.77), renal disease (OR = 1.53), 
arterial thromboembolism (OR  =  1.45), pulmonary disease 
(OR = 1.37), and anemia (OR = 1.35) (32) are strongly associ-
ated with VTE risk in cancer patients. Not surprisingly then, 
in a study on patients with ovarian cancers, Rodriguez et  al. 
observed that the risk of VTE continued to increase with the 
number of such comorbid conditions; (HR  =  2.1 with one 
comorbidity, HR = 2.6 with two comorbidities and HR = 3.9 
with ≥ three comorbidities) (44).
TABLe 2 | Predictive model for chemotherapy-associated vTe (62).
Patient characteristics Risk score
Site of cancer
Very high risk (stomach, pancreas) 2
High risk (lung, lymphoma, gynecologic, bladder, testicular) 1
Prechemotherapy platelet count ≥350,000/μL 1
Hemoglobin <10 g/dl or use of RBC growth factors 1
Prechemotherapy leukocyte count >11,000/μL 1
Body mass index ≥35 kg/m2 1
High risk defined as risk score ≥3. VTE, venous thromboembolism.
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Finally, one must obtain a detailed family history when 
 assessing a patient’s thrombotic risk. This is important as a num-
ber of predisposing genetic factors, such as Factor V Leiden and 
Prothrombin gene mutations are known to confer an increased 
risk of VTE in cancer patients when compared to those without 
the mutations (63, 67). Even when the above-mentioned factors 
have been evaluated, a comprehensive VTE risk assessment in 
the cancer patient is incomplete until weighed in the context of 
their functional status. In a prospective study on patients with 
non-small cell lung carcinoma receiving chemotherapy, VTE 
developed in 31% patients with poor performance status as 
compared to 15% with better performance status (26).
A Risk Model for  
Chemotherapy-Associated vTe
In order to reduce the disease burden of VTE, it is important to 
identify cancer patients at high risk for VTE and who may, therefore, 
benefit from thromboprophylaxis. Conversely, identifying patients 
at low risk for VTE may allow us to determine those patients in 
whom prophylactic anticoagulation can be foregone in order to 
mitigate the risk of iatrogenic bleeding. Though both intuitive and 
appealing, the utility of such an approach has had conflicting results 
(68–70). Recently, a validated risk model for use in the ambulatory 
setting was published to identify cancer patients whom are at high 
risk for VTE (Table 2) (62). Five predictive variables were identified 
in the development cohort, before initiation of chemotherapy. Rates 
of VTE in the development cohort were 0.8% in the low-risk category 
(score = 0), 1.8% in the intermediate risk category (score = 1–2), and 
7.1% in the high risk category (score = 3 or above), while rates in the 
validation cohorts were 0.3, 2, and 6.7%, respectively (over a median 
period of 2.5 months, C statistics = 0.7 for both cohorts).
The model has a negative predictive value of 98.5% at the 
cutoff point for high risk (score ≥ 3). This score is being used to 
define cancer patients at high risk for VTE in a study on throm-
boprophylaxis.1 Additionally, this model is being assessed for its 
use in clinical practice as well.2
PROPHYLAXiS OF veNOUS 
THROMBOeMBOLiSM
Prevention of Postoperative vTe
In surgical oncology patients without thromboprophylaxis, the 
incidence of lower extremity DVT, as shown by venography, 
1 www.clinicaltrials.gov NCT 00876915
2 www.clinicaltrials.gov No. NCT01602432
ranges from 40 to 80% while that of proximal DVT varies between 
10 and 20%. The risk of fatal postoperative PE associated with 
cancer surgery is about four times higher in comparison to non-
oncologic surgery (71). Strong risk factors associated with VTE 
in this setting have been described above (treatment-related risk 
factors). One commonly used prophylactic regimen consists of 
a pre-operative dose of subcutaneously administered Heparin, 
followed by scheduled dosing 12–24 h postoperatively. Typically, 
unfractionated Heparin (UFH) is given two to three times a day 
and low molecular weight Heparin (LMWH) is injected once 
daily. International guidelines direct the use of anti-thrombotic 
prophylaxis for at least 7–10 postoperative days in patients with 
cancer surgery (5, 72–74).
Enoxaparin and Cancer (ENOXACAN) II was the first study 
to demonstrate the benefits of extended thromboprophylaxis with 
enoxaparin in reducing postoperative VTE among cancer patients 
undergoing surgery (75). These benefits have been demonstrated 
across a wide range of patient profiles among oncologic patients, 
including those undergoing abdominal, pelvic, and thoracic 
surgery. Rasmussen et  al. showed that prolonged prophylaxis 
with LMWH significantly reduces the risk of VTE compared 
with prophylaxis given for 7–10  days, without an increase in 
bleeding complications (76). The overall incidence of VTE was 
14.3% (95% CI, 11.2–17.8%) in the control group as compared to 
6.1% (95% CI, 4.0–8.7%) in the patients receiving out-of-hospital 
LMWH (76). The ESMO and AIOM guidelines (73, 74) recom-
mend extended prophylaxis for all patients undergoing elective 
cancer surgery while the ASCO panel (5) recommends extended 
prophylaxis for up to 4  weeks in patients undergoing major 
abdominal or pelvic cancer surgery in the presence of strong risk 
factors (please see above).
If pharmacologic prophylaxis is contraindicated, mechanical 
prophylaxis, such as continued use of intermittent pneumatic 
compression devices with or without compression stockings, 
should be employed. If compression stockings are used, it is 
important to ensure that they are of the appropriate size in order 
to be effective in preventing DVT (77).
Prevention of vTe-Related to  
Long-Term CvC
The incidence of asymptomatic CVC-related DVT has 
been reported to be about 20% while that of overt DVT 
of the upper extremities ranges between 2 and 4% (71). 
Thromboprophylaxis for CVC-related thrombosis is contro-
versial. Both LMWH and Warfarin have been found to be safe 
and effective in these patients (68, 70, 78, 79). International 
guidelines, however, do not recommend routine prophylaxis 
for this indication (5, 73, 74).
Prevention of  
Chemotherapy-Associated vTe
In one of the earliest studies examining this topic, Levine et al. 
reported that low-dose Warfarin is safe and effective for VTE 
prevention in stage IV breast cancer patients receiving chemo-
therapy, the relative risk reduction vs. placebo being 85% (80). 
TABLe 3 | Recommended anticoagulant regimens for venous 
thromboembolism prophylaxis and treatment in patients with cancer.
Management Drug Regimen
Prophylaxis
Unfractionated 
heparin
5,000 IU SQ, every 8 h
Dalteparin 5,000 IU SQ, daily
Enoxaparin 40 mg SQ, daily
Tinzaparin 2.5 mg SQ, daily
Fondaparinux 75 IU/kg SQ, daily
initial treatment
Unfractionated 
heparin
80 IU/kg IV bolus, then 18 IU/kg/h IV
Dalteparin* 100 IU/kg SQ every 12 h or 200 IU/kg SQ 
every 24 h
Enoxaparin* 1 mg/kg SQ every 12 h or 1.5 mg/kg SQ 
daily
Tinzaparin 175 IU/kg SQ daily
Fondaparinux* <50 kg: 2.5–5 mg SQ, daily
50–100 kg: 5–7.5 mg SQ, daily
>100 kg: 7.5–10 mg SQ, daily
Long-term treatment
Dalteparin 200 IU/kg SQ daily × 1 month then  
150 IU/kg SQ daily
Warfarin 5–10 mg PO daily, adjust dose to INR 
2.0–3.0
*Avoid in patients with creatinine clearance <35 ml/min or adjust dose based on anti-
factor Xa level.
Modified from Verso et al. (71).
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In the more recent PROTECHT study, Nadroparin use was 
found to be associated with a statistically significant 50% 
relative risk reduction in thromboembolic events among cancer 
patients in the ambulatory setting receiving chemotherapy for 
advanced cancers of the breast, lung, gastrointestinal tract, 
head/neck region, ovary, and pancreas. Fifteen (2.0%) of 769 
patients treated with Nadroparin and 15 (3.9%) of 381 patients 
treated with placebo had a thromboembolic event (single-sided 
P = 0.02) (81).
Thromboprophylaxis with Certoparin; a LMWH, primar-
ily active against factor Xa, was evaluated in the TOPIC-1 and 
TOPIC-2 studies that examined patients with advanced breast 
cancer (TOPIC-1) and stage III/IV non-small cell lung cancer 
(TOPIC-2), respectively (69). VTE occurrence was not dif-
ferent between the treatment groups in TOPIC-1 (4% treated 
with Certoparin vs. 4% receiving placebo, OR =  1.02, 95% CI, 
0.3–3.48) and TOPIC-2 [which showed a non-significant trend 
toward efficacy in lung cancer group (4.5 vs. 8.3%, OR = 0.52, 
95% CI, 0.23–1.12)].
More recently, Semuloparin, a novel ultra LMWH, was tested 
for its safety and efficacy in preventing VTE among patients 
with advanced solid cancers receiving chemotherapy (82). 
In a double-blind, multicenter trial, patients were randomly 
assigned to receive subcutaneous Semuloparin 20 mg once daily, 
or placebo. The primary efficacy outcome was the composite 
of any symptomatic DVT, any non-fatal PE, and VTE-related 
death. VTE occurred in 20 of 1,608 patients (1.2%) receiving 
Semuloparin, compared with 55 of 1,604 patients (3.4%) on 
placebo (HR: 0.36; 95% CI, 0.21–0.60). Major bleeding rates of 
patients receiving Semuloparin and placebo rates were similar, 
occurring in 1.2 and 1.1%, respectively (HR: 1.05; 95% CI, 
0.55–1.99).
International guidelines do not recommend routine prophy-
laxis of cancer patients in the ambulatory setting who receive anti-
neoplastic agents (5, 72–74). In this setting, thromboprophylaxis 
is only recommended for patients with Multiple Myeloma on 
Thalidomide or Lenalidomide-based combination chemotherapy. 
Table 3 summarizes the commonly used anticoagulant regimens 
for VTE prophylaxis.
Special Considerations in Patients with 
Acute Leukemia and Hematopoietic Stem 
Cell Transplant Recipients
Patients with acute leukemia and hematopoietic stem cell trans-
plant (HSCT) recipients present a special challenge in this regard 
as both groups are at great risk for both thrombotic and bleeding 
events. The incidence of VTE in patients with acute leukemia, for 
example, ranges from 1.7 to 12% (83). Thrombocytopenia expe-
rienced by many of these patients as a result of chemotherapy 
places them at great risk for bleeding complications. In one 
retrospective study, of 1,514 HSCT transplant recipients, 4.6% 
patients developed symptomatic VTE within 180 days of HSCT 
(84), while 3.6% of patients had had a fatal bleeding episode. 
Randomized clinical trials are required in order to devise the 
best regimen for VTE prophylaxis in this high-risk patient 
population.
TReATMeNT OF veNOUS 
THROMBOeMBOLiSM
Venous thromboembolism treatment in cancer patients is no 
different from that of other medical patients. While diagnostic 
evaluation is underway, anticoagulation should be started in 
all patients in whom VTE is a serious consideration. Options 
for acute management include adjusted-dose UFH, fixed dose 
LMWHs or Fondaparinux. Options for chronic anticoagulation 
have been summarized in Table 3. If an oral Vitamin K antagonist 
(VKA) is chosen, initial overlap with a parenteral agent (e.g., 
UFH, etc.) is required for at least 5–7 days until the international 
normalized ratio (INR) is between 2 and 3 for at least 24 h. Studies 
have shown that in patients with advanced cancers, LMWHs 
significantly reduce the incidence of recurrent VTE (by as much 
as 50% in some studies) when compared to oral VKA, without 
any difference in bleeding complications (85–88). LMWHs also 
have the advantage of simplifying initial treatment, thus, mak-
ing it feasible to manage VTE in the outpatient setting as well. 
According to international guidelines, LMWHs are preferable to 
full dose Warfarin for initial treatment of cancer-related VTE, 
particularly in the first 3–6 months (5, 72–74). In these patients, it 
is recommended that subsequent anticoagulant therapy with oral 
VKAs or LMWHs should be continued indefinitely or until the 
cancer has resolved. The safety and efficacy of LMWHs in cancer 
patients beyond a treatment duration of 6 months is unknown but 
currently under investigation.3
3 www.clinicaltrials.gov, NCT00942968
TABLe 4 | Therapeutic recommendations for venous thromboembolism in cancer.
Deep vein 
thrombosis  
(DVT)
• LMWH for acute and chronic therapy
• UFH, LMWH or Fondaparinux with transition over 5–7 days to Warfarin (INR 2–3) is an acceptable alternative if LMWH not feasible
• Duration at least 3 months or for as long as cancer active (whichever is longer)
• For massive DVT, consider catheter-directed pharmacomechanical thrombolysis
• If anticoagulation contraindicated, consider retrievable vs. permanent vena cava filter
Pulmonary 
embolism
• LMWH for acute and chronic therapy
• UFH, LMWH or Fondaparinux with transition over 5–7 days to Warfarin (INR 2–3) is an acceptable alternative if LMWH not feasible
• Duration at least 6 months or for as long as cancer active (whichever is longer)
• For massive PE, consider thrombolytic therapy
• If anticoagulation contraindicated, consider retrievable vs. permanent vena cava filter
CVC-related  
DVT
• Initial therapy with UFH, LMWH or Fondaparinux with transition over 5–7 days to Warfarin (INR 2–3)
• Remove catheter if symptoms fail to improve or catheter no longer needed
• Duration at least 3 months or for as long as catheter is present (whichever is longer)
• For massive CVC-related DVT consider thrombolytic therapy
Superficial 
venous 
thrombosis
• If distal, consider symptomatic therapy with compresses, NSAID’s and continued observation
• If proximal (above knee), consider LMWH with or without transition to Warfarin (INR 2–3) particularly with clots within 2cm of deep venous system
• Duration of therapy 1–3 months
Calf vein  
thrombosis
• Initial therapy with UFH, LMWH, or Fondaparinux with transition over 5–7 days to Warfarin (INR 2–3) or LMWH for acute and chronic therapy
• Duration of therapy 3 months
• If anticoagulation contraindicated, consider serial duplex surveillance
• If calf vein DVT progresses to involve proximal deep veins and anticoagulation is contraindicated, consider retrievable vs. permanent vena cava filter
Recurrent 
VTE
• If currently on Warfarin switch to LMWH or treat for 5–7 days with UFH, LMWH, or Fondaparinux in transition to therapeutic INR (if INR sub 
therapeutic at time of event)
• If on LMWH- check dose, consider LMWH level vs. empiric dose increase, switch to Fondaparinux
• If recent initiation of UFH or LMWH, consider HIT
• Look for anatomic reason for recurrence
• Consider vena cava filter
Vena Cava 
filter
• If a retrievable filter is placed, follow the patient closely and retrieve the filter when anticoagulation is no longer contraindicated
• If a permanent filter is placed and anticoagulation is no longer contraindicated, consider indefinite anticoagulation
Adapted from Streiff (95).
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In an observational study, Kovacs et  al. noted that upper 
extremity DVTs secondary to central catheters in cancer patients 
respond well to anticoagulation without removal of the cath-
eter (89). Therefore, it is preferable in this setting to treat upper 
extremity DVT without removal of the CVC. Guidelines further 
recommend that anticoagulation should be continued for as 
long as the catheter is in place and for at least 3 months after its 
removal (90).
The significance of diagnosing and treating calf vein DVT has 
been questioned in the past (91, 92). In an observational study by 
Galanaud et al., no difference in the proportion of recurrent VTE 
between patients with distal DVT or isolated proximal DVT was 
detected (93). In a randomized study on patients with calf vein 
thrombosis, Lagerstedt et  al. observed that progressive throm-
boembolism developed in 29% of the patients in the absence 
of 3  months of oral anticoagulation therapy (94). The NCCN 
guidelines recommend a minimum of 3 months of therapy until 
larger studies supporting a shorter treatment duration become 
available (95). Given the inherent risk of major and rarely fatal 
bleeding (96, 97), the NCCN guidelines recommend that throm-
bolytic therapy should be restricted to life- or limb-threatening 
thrombotic events (95).
Vena cava filter insertion is commonly performed for recur-
rent PE, extension of DVT while on anticoagulation, and in 
instances where anticoagulation is contraindicated. Their use, 
however, is not associated with any mortality benefit based 
on results from observational studies and large randomized 
controlled trials (9, 98–100). Additionally, there are serious 
safety concerns for complications, such as filter thrombus, 
embolization, fatal PE as well as fracture, and migration of 
retrievable filters (9, 101, 102). The NCCN guidelines, there-
fore, recommend that Vena Cava filters should only be used 
in the setting of acute VTE where a patient cannot receive 
anticoagulation.
A large randomized clinical trial evaluating thrombolytic 
therapy for sub-massive PE failed to show any mortality benefit 
(103). Additionally, there were concerns for bleeding complica-
tions with this form of therapy. The NCCN guidelines, therefore, 
recommend that use of systemic thrombolytics be reserved for 
massive PE. Recommendations for superficial venous thrombosis 
have been summarized in Table 4.
Recurrent VTE despite adequate anticoagulation is not 
uncommon among cancer patients and an empiric approach 
has been proposed for such instances (104, 105). In all cases 
of symptomatic recurrent VTE, it is important to ensure drug 
compliance. Heparin-induced thrombocytopenia (HIT) must 
also be excluded. Patients on treatment with oral VKA should 
be switched to LMWH and those being managed with LMWH 
should have an increase in their dose by 25% (or increased to 
weight adjusted doses if receiving lower doses) (106, 107). In 
7Qureshi et al. Thromboembolism in Cancer Patients
Frontiers in Cardiovascular Medicine | www.frontiersin.org July 2016 | Volume 3 | Article 24
patients who do not respond, another dose escalation should be 
considered and an anti Xa level may be used to estimate the next 
dose escalation (108). Anatomic risk factors that may account for 
recurrent thrombosis (e.g., target vessel compression by tumor, 
May–Thurner syndrome, Thoracic outlet syndrome) should 
be excluded. Vena cava filter insertion may also be considered 
though this intervention has no impact on patient survival as 
described above.
Bemiparin
Bemiparin is a LMWH with anti-factor Xa/anti-factor IIa activity 
that has been studied for VTE prophylaxis in cancer patients under-
going abdominal or pelvic surgery (109). In the CANBESURE 
study, 703 cancer patients undergoing surgery were randomized 
to receive 3,500 IU of Bemiparin subcutaneously daily for 8 days. 
They were then randomized to receive Bemiparin or placebo for 
an additional 20 days. Major VTE occurred in 0.8% of patients in 
the Bemiparin group compared with 4.6% in the placebo group 
(relative risk reduction 82.4%; 95% CI, 21.5–96.1%; P = 0.010). 
The study authors concluded that 4  weeks of Bemiparin use 
(when compared to 1 week of Bemiparin) significantly reduced 
the rate of major VTE without an associated increase in bleeding 
risk in cancer patients undergoing surgery.
Semuloparin
Semuloparin is a subcutaneous ultra LMWH that acts as a factor 
Xa inhibitor with residual factor IIa activity (110). The TREK 
study evaluated the dose–response profile of Semuloparin in 
patients undergoing total knee replacement (110). A significant 
dose–response correlation was observed across five tested doses 
of Semuloparin and the incidence of VTE ranged from 5.3% (at a 
dose of 60 mg/day) to 44.1% (at a dose of 10 mg/day). A similar 
dose–response effect was observed for incidents of major bleed-
ing (P = 0.0231).
It was concluded that a dose between 20 and 40 mg/day pro-
vides an adequate benefit-to-risk profile. Agnelli et al. evaluated 
Semuloparin for thromboprophylaxis in cancer patients receiving 
chemotherapy (82).
Parenteral Factor Xa inhibitors
Fondaparinux is a synthetic pentasaccharide that acts by binding 
to antithrombin and increasing its inhibitory effect against factor 
Xa by a factor of ~300. Turpie et al., in a meta-analysis of four 
multicenter, randomized, double-blind trials, evaluated the safety 
and efficacy of Fondaparinux in comparison with Enoxaparin 
(111). The incidence of VTE was reduced by half from 13.7% 
with LMWH to 6.8% with Fondaparinux. The US Food and Drug 
Administration has approved Fondaparinux as a substitute for 
Heparin or LMWH in the initial treatment of VTE. Additional 
studies are needed to evaluate the safety and efficacy of this agent 
in patients with malignancy.
Oral Direct Factor Xa inhibitors
Rivaroxaban (109, 112–115) and Apixaban (116–118) are 
two promising oral inhibitors of factor Xa that have been 
predominantly studied for prevention of VTE in patients under-
going orthopedic surgery.
In one study, extended duration prophylaxis with Rivaroxaban 
(10  mg once daily for 35  days) was compared with shorter 
duration prophylaxis with Enoxaparin (40  mg once daily for 
10 days) in acutely ill medical patients, including patients with 
cancer (MAGELLAN trial) (119). The primary efficacy outcomes 
were symptomatic VTE, VTE-related death, or asymptomatic 
proximal DVT detected by routine compressive ultrasonography. 
Rivaroxaban was associated with a reduction in the risk of venous 
thrombosis compared to 10 days of treatment with Enoxaparin. 
Bleeding rates were significantly increased with this new factor 
Xa inhibitor.
In an interim analysis of a phase II trial, Levine et al. noted that 
Apixaban was well tolerated by patients with metastatic cancer. 
The incidence of major bleeding and thrombosis were very low 
among 125 patients (two patients receiving Apixaban at a dose 
of 20 mg and one patient in the placebo group developed major 
bleeding). Thrombosis was reported among three cases in the 
placebo group (120).
Edoxaban, another oral direct factor Xa inhibitor has been 
recommended as an alternative agent to treat VTE in cancer 
patients by the latest Chest guidelines (Grade 2C) (121). In 
an indirect comparison with apixaban, rivaroxaban, and 
dabigatran; edoxaban did not show statistically significant dif-
ference in risk of recurrent VTE or all – cause mortality (122). 
In addition, for the composite end – point of major or clinically 
relevant non-major bleeding, the relative risk for apixaban vs. 
edoxaban was 1.50 (95% CI, 1.17–1.92, P =  0.001), was 1.15 
(95% CI, 0.95–1.39, P = 0.16) for rivaroxaban vs. edoxaban and 
1.31 (95% CI, 1.02–1.68, P = 0.04) for edoxaban vs. dabigatran. 
However, this analysis did not look at the cancer patients. 
Therefore, edoxaban appears a safer alternative to Warfarin 
except patients with creatinine clearance >95 ml/min in whom 
it had shown to increase the risk of ischemic stroke. It does 
carry the benefit of once a day dosing as compared to its con-
temporary agents.
Oral Direct Thrombin inhibitors
Ximelagatran was the first oral direct thrombin inhibitor studied 
in clinical trials but its development was discontinued because 
of potentially severe hepatotoxicity. Dabigatran etexilate is the 
most developmentally advanced oral direct thrombin inhibitor. 
In randomized, double-blinded trials, it has been shown to be 
non-inferior to LMWH in reducing the risk of major VTE in 
patients undergoing orthopedic surgery.
CONCLUSiON
Thromboembolism in cancer patients is associated with significant 
consequences, including its association with morbidity, mortality, 
the need for long-term anticoagulation, and its consumption of 
healthcare resources. Recent studies have enabled us to better 
understand its clinical risk factors. New oral  anticoagulants 
 present an attractive treatment option because of their ease of 
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(oral) administration and their lack of need for laboratory moni-
toring. Some of their limitations include:
 (a) Published data on the safety and efficacy of NOACs in 
cancer-associated VTE is lacking. In clinical trials evaluat-
ing NOACs in VTE treatment, a very small percentage 
of the study population randomized to receive a NOAC 
had a diagnosis of cancer. Therefore, it remains unknown 
whether the safety and efficacy outcomes observed in these 
trials of largely non-cancer patients also apply to cancer 
patients.
 (b) Recent trials comparing Fondaparinux or Rivaroxaban with 
LMWH have shown that specific factor Xa inhibition might 
be less efficacious than LMWH inhibition in cancer patients 
(123, 124).
 (c) The oral administration route may not be practical in patients 
experiencing nausea, vomiting, and diarrhea as side effects of 
chemotherapy.
 (d) No antidote is available to reverse the anticoagulant effects of 
these agents.
 (e) The lack of assays to measure their anticoagulant effect 
makes it difficult to manage patients presenting with recur-
rent thrombosis or bleeding.
 (f) Drug–drug interactions with anti-neoplastic agents may 
lead to clinically important changes in drug levels (105). The 
ISTH guidance statement, therefore, recommends against 
the use of NOACs for the treatment of cancer-associated 
thrombosis (108). It is imperative that the efficacy and safety 
of these agents be investigated in randomized controlled 
trials, specifically, in cancer patients with VTE.
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